Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2023 | ASCO GU 2023: hot topics in prostate cancer

Alan Haruo Bryce • 18 Feb 2023
GU Cancers 2023
Genitourinary Cancer Prostate Cancer

Alan Haruo Bryce, MD, Mayo Clinic, Rochester, MN, discusses highlights in prostate cancer from the ASCO GU Cancers Symposium 202, including, new data in radiation oncology for early-stage disease, optimal pairing of androgen deprivation therapy for patients undergoing salvage radiation therapy and AI-based risk stratification tools. Additionally, data on multiple treatment modalities besides PARP inhibitors was discussed, including bispecific T-cell engagers, radioligand therapy such as lutetium-177, and androgen receptor degraders, amongst many more. This interview took place at the ASCO GU Cancers Symposium 2023 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Alan Haruo Bryce

0:36
The clinical impact of TRITON3 on the potential role of rucaparib in the future treatment of mCRPC
Alan Haruo Bryce • 16 Feb 2023
2:02
Unanswered questions regarding the use of PARP inhibitors for patients with mCRPC
Alan Haruo Bryce • 16 Feb 2023
2:59
TRITON3 interim OS results demonstrate superiority of rucaparib over docetaxel for mCRPC
Alan Haruo Bryce • 16 Feb 2023

Related Videos

2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
3:07
Serum thymidine kinase 1 as a predicative biomarker in prostate cancer
Teemu Murtola • 9 Apr 2024
0:57
Real-world outcomes of 177Lu-PSMA-617 in mCRPC
Hannah McManus • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals